Eli Lilly suffers setback in Alzheimer’s treatment plans

Eli Lilly Alzheimer’s drug could slow disease, but comes with side effectsПодробнее

Eli Lilly CEO: Alzheimer's drug trial shows slowed disease progression by 40-60% in early patientsПодробнее

Lilly drug slows Alzheimer's progression by 35% in trialПодробнее

FDA postpones approval for experimental Alzheimer's drugПодробнее

FDA delays Lilly's Alzheimer's drug approvalПодробнее

A new experimental drug shows promise in fight against Alzheimer'sПодробнее

Eli Lilly study shows Alzheimer's drug slows diseaseПодробнее

Sponsor Perspective: Eli Lilly | Expanding Access to Alzheimer’s Care & TreatmentПодробнее

Alzheimer's Drug DelayedПодробнее

‘Remarkable’ drug reduces Alzheimer’s decline, study showsПодробнее

Eli Lilly: Working Together Towards Better Patient Outcomes #WeWontRestПодробнее

Eli Lilly's Alzheimer's drug slowed cognitive decline in phase 3 studyПодробнее

FDA delay's Eli Lilly's experimental Alzheimer's drugПодробнее

Promising data from Eli Lilly shows a significant slowdown in the pace of Alzheimer'sПодробнее

Jim's Alzheimer's StoryПодробнее

Eli Lilly CEO on FDA approval pathway for Alzheimer's drugsПодробнее

Eli Lilly CEO on slashing insulin prices, approval timelines for weight-loss and Alzheimer's drugsПодробнее

Eli Lilly Alzheimer's Drug Fails Major Test TrialПодробнее

Eli Lilly CEO David Ricks on positive Alzheimer's drug trial dataПодробнее